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ABSTRACT
Aim of study. To analyse Polish neurologists’ familiarity with the diagnostic criteria for migraine, and how their methods of 
management of migraine work in daily practice. 
Clinical rationale for study. Migraine is a common primary headache disease that causes substantial disability and reduces 
quality of life. Many migraine patients remain undiagnosed and deprived of treatment. Migraine treatment is problematic, and 
many patients discontinue preventive treatment, mainly because of a lack of efficacy or adverse effects. Antibodies targeting 
calcitonin gene-related peptide and its receptor seem to be effective and well-tolerated agents in migraine prevention.
Material and methods. This study was conducted using a computer-assisted web interview conducted with 51 neurologists in 
Poland, who agreed to participate in the study during a phone call. The questionnaire mainly assessed methods of treatment of 
migraine patients and diagnostic criteria used in neurological practice.  
Results. Only one neurologist listed all of the diagnostic criteria for migraine, and 80% of physicians in their practice used only 
a part of the migraine diagnostic criteria, usually the migraine without aura criteria. On average, each neurologist had 55 patients 
under continuous care, seeing roughly 18 patients per month. On average, neurologists estimated that 77% of all patients with 
migraine had episodic migraine, whereas the rest had the chronic form. Importantly, 40% of patients with chronic migraine 
received all available preventive treatments without a satisfactory effect. Neurologists could offer monoclonal antibodies that 
target the CGRP-pathway (i.e. anti-CGRP and anti-CGRP receptor monoclonal antibodies) for the prevention of chronic migraine 
to about one in three patients with a chronic form of the disease.
Conclusions and clinical implications. Migraine is underdiagnosed and undertreated in Poland. Understanding of the diag-
nostic criteria for migraine among neurologists is insufficient. Most neurologists in Poland see patients in whom anti-CGRP/R-
-targeting treatment is indicated.
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Introduction
Migraine is a common primary headache disease that 
causes substantial disability and seriously affects quality of life. 
Globally, migraine is the second highest cause of years lived 
with disability, and it is the most common cause for referrals 
to a neurologist [1, 2]. It is estimated that migraine affects 
15–18% of women and 6% of men [3]. However, many people 
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with migraine remain undiagnosed; about a quarter of patients 
with headaches meeting the diagnostic criteria for migraine 
do not receive a proper diagnosis [4]. In an online survey 
among Polish adults, 25% had reported migraine symptoms 
within the previous 12 months, 2.5% had experienced migraine 
attacks with aura only, 6.4% had experienced migraine attacks 
without aura, and 16.2% had experienced migraine attacks 
with or without aura. 37% of people with migraine declared 
that they had had migraine diagnosed by a physician in the 
past. 43% of people suffering from migraine attacks received 
medical advice for their condition; in the majority of cases 
they were referred to a primary care physician/general practi-
tioner (71%), or slightly less frequently to a neurologist (48%) 
[5]. Similarly, in a large population study in Poland, 8.5% of 
participants had migraine; there are no other reliable studies 
except those quoted here [6]. 
In the USA, the National Hospital Interview Survey 
showed that the overall prevalence of migraine or severe he-
adache was 15.3% [7]. Chronic migraine affects 1.4–2.2% of 
the general population, with a 2.5–6.5-fold greater prevalence 
among women [8]. Compared to episodic migraine, chronic 
migraine poses a greater burden for patients and their families 
and generates three times more healthcare costs. In addition 
to frequent headaches, patients with chronic migraine often 
present anxiety, depression, obesity, and disorders of the 
respiratory, cardiovascular, and gastrointestinal systems [9].
The International Classification of Headache Disorders, 
3rd. Edition (ICHD-III) defines chronic migraine as a heada-
che occurring on 15 or more days per month for three months 
or longer, with features of a migraine headache on eight or 
more days per month [10]. Some have even suggested that 
having a migraine headache on eight or more days per month 
should itself be sufficient to define chronic migraine, because 
such patients have a disabling disease that requires effective 
treatment [4, 10, 11]. 
There are three main aspects to managing migraine: life-
style changes which include the recognition and avoidance of 
migraine triggers, the treatment of acute attacks, and preven-
tive treatment. The most common migraine triggers include 
fasting, alcohol, caffeine withdrawal, or specific foods [12]. 
Effective treatment, acute and preventive, reduces the risk 
of progression and improves the outcome in patients with 
migraine [13].
Acute migraine should be treated pharmacologically, with 
nonsteroidal anti-inflammatory drugs, triptans, antiemetics, 
or, less commonly, ergots, all together being the first-line me-
dications [14, 15]. Preventive treatment should be considered 
in patients with chronic migraine or episodic migraine with 
frequent attacks, when the frequency or severity of headaches 
interferes substantially with work, school, or social life. Many 
drugs are used for preventive treatment, including β-blockers, 
calcium channel blockers, antidepressants, and anticonvul-
sants, as well as botulinum toxin, although this last-named is 
used exclusively in chronic migraine.
Moreover, because calcitonin gene-related peptide (CGRP) 
is crucially implicated in the pathogenesis of migraine, monoc-
lonal antibodies that target CGRP or its receptor (CGRP-R) 
have been developed to prevent both chronic and episodic 
migraine [16, 17]. On average, these agents shorten the dura-
tion of migraine by about a week per month [18]. The drugs 
for preventive treatment are chosen based on the headache 
pattern, comorbidities, medication tolerability, and patient 
preferences. 
In practice, many patients discontinue classical/phar-
macological preventive treatment, mainly because of a lack 
of efficacy or adverse effects. Thus, there is a need for highly 
tolerable and effective preventive treatments for migraine [19].
Clinical rationale for this study
Migraine is an underdiagnosed and undertreated disease 
in Poland. Greater knowledge in the field of migraine diag-
nosis will help neurologists estimate the number of patients 
who require treatment, including monoclonal antibodies that 
target the CGRP-pathway. The aim of this study was to analyse 
Polish neurologists’ familiarity with the diagnostic criteria for 
migraine and their management preferences for migraine in 
daily practice, including the latest recommendations. 
Materials and methods
In June and July 2019 we conducted a computer-assisted 
web interview with neurologists in Poland, who had agreed 
to participate in the study during a phone call. 
The inclusion criteria were as follows:
 — Specialisation in neurology (board certification)
 — Seeing eight or more patients with migraine per month
 — Seeing patients with chronic migraine
 — Initiating treatment for chronic migraine 
The neurologists filled out a questionnaire (spontaneous 
answer, open-ended question) that assessed:
 — Knowledge of the diagnostic criteria for migraine 
 — Number of patients with episodic or chronic migraine 
under their care
 — Treatment options of episodic and chronic migraine
 — Preventive treatment for chronic migraine
 — Need for new therapies in migraine
 — Knowledge of anti-CGRP and/or anti-CGRP-R monoc-
lonal antibodies.
Results
A total of 51 neurologists, with a mean experience in 
neurology of 17.2 years, completed the questionnaire. Only 
one neurologist (~2%) knew the exact definition of, and listed 
all the diagnostic criteria for, migraine without and with aura. 
Five (~10%) neurologists listed all the diagnostic criteria for 
migraine without aura, 80% of physicians in their practice 
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Figure 1. Percentages of neurologists declaring the number of patients under continuous care and the number of patients seen per month
used only a part of the migraine diagnostic criteria, usually 
migraine without aura criteria, and a large proportion of 
them (29% of neurologists) listed very limited criteria. Nine 
(18% of neurologists) did not list any diagnostic criteria for 
migraine (Fig. S1).
Thirty-six (71%) neurologists provided care to patients 
with migraine in a public outpatient clinic. Thirty-four (67%) 
neurologists provided care for patients with migraine in 
hospital. Figure 1 shows the percentages of neurologists dec-
laring the number of patients under continuous care and the 
number of patients per month. On average, each neurologist 
had 55 (median 40) patients under continuous care, seeing 
a mean of 18 (median 12) patients per month. On average, 
neurologists estimated that 77% of all patients with migraine 
had episodic migraine, whereas the rest had chronic migraine. 
On average, neurologists estimated that 8% of patients with 
episodic migraine (which is one patient per month) required 
sick leave, with a mean absence of four days. Among patients 
with chronic migraine, 22% required sick leave (which is one 
patient per month), with a mean absence of seven days.
Treatment for episodic migraine
Each neurologist provided care to an average of 42 pa-
tients with episodic migraine. On average, 78% of patients 
with episodic migraine received prescription drugs, 19% 
received over-the-counter (OTC) drugs only, and 3% did not 
receive any drugs. Of patients who received pharmacological 
treatment, 53% received acute treatment only, 41% received 
preventive and acute treatment, and 6% received preventive 
treatment only (Fig. S2). 
Thirty-four (67%) neurologists initiated preventive the-
rapy based on the number of days with migraine headaches 
in a month, with an average of seven days being sufficient to 
start treatment. Neurologists estimated that, among patients 
with episodic migraine, 36% overused OTC analgesics and 
8% overused triptans. 
Treatment for chronic migraine
On average, each neurologist provided care to 13 patients 
with chronic migraine. Most of these patients (84%) received 
prescription drugs, 6% received OTC treatment ordered by 
a neurologist, 9% self-medicated with OTC drugs, and 1% did 
not receive any drugs. Most patients with chronic migraine 
(78%) received preventive and acute treatment, 14% received 
acute treatment only, and 8% received preventive treatment 
only (Fig. 2). 
Twenty-seven neurologists (53%) initiated preventive 
treatment based on the number of days with a migraine he-
adache in a month, with cut-off values ranging from three to 
16 days. Eighteen of them initiated preventive treatment in 
their patients when the total length of time with a migraine 
headache in a month was 14-16 days (average > 12 days). Fif-
teen (29%) neurologists initiated preventive treatment based 
on the number of days with a headache in a month, and nine of 
them used the cut-off value of 14-15 days (average > 12 days). 
On average, of patients with chronic migraine on preven-
tive treatment, 39% received anticonvulsants, 24% received 
β-blockers, and 22% received calcium channel blockers (Fig. S3). 
Among patients with chronic migraine, 54% overused OTC 
analgesics and 18% overused triptans.
Twenty-nine (57%) neurologists initiated preventive 
therapy for chronic migraine with anticonvulsants, 19 (37%) 
with β-blockers, and 18 (35%) with calcium channel blockers. 
First-line preventive treatment was effective in 64% of patients; 
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Figure 2. Medications and treatment types for chronic migraine
28% of patients switched to a second-line drug, and 9% di-
scontinued first-line treatment. Thirty-six (71%) neurologists 
used anticonvulsants as second-line preventive treatment for 
chronic migraine. Second-line treatment was effective in 58% 
of patients; 31% of patients switched to a third-line drug, and 
11% of patients discontinued second-line treatment. Twenty-
-four (47%) neurologists used anticonvulsants as third-line
preventive treatment; botulinum toxin was prescribed by nine 
(18%) neurologists. Third-line treatment was effective in 49% 
of patients; 32% of patients switched to a fourth-line drug, and 
19% discontinued third-line treatment. Twenty-seven (53%)
neurologists did not try fourth-line preventive treatment, and 
36 (70%) did not try fifth-line preventive treatments. Preven-
tive treatment was discontinued due to a lack of effectiveness 
(34% of patients), patient decision (30%), or adverse effects
(19%). On average, each neurologist had about five (40%)
patients with chronic migraine, who had received all possible 
treatments in their opinion. On average, each neurologist co-
uld offer anti-CGRP/R-targeting treatment to 4.2 patients i.e. 
33% of patients with chronic migraine, and 8% of all patients 
with migraine.  Figure S4 shows the percentages of neurolo-
gists declaring the number of patients with chronic migraine
who used all possible treatments and the number of patients
who could be offered anti-CGRP or anti-CGRP-R treatment.
Forty-one (80%) neurologists were aware that anti-CGRP 
and/or anti-CGRP-R monoclonal antibodies were available 
in Poland. Forty neurologists (78%) knew that erenumab was 
approved in Poland. Four (8%) neurologists declared that 
eptinezumab was available in Poland, which is not yet true. 
Nine (18%) neurologists did not know of any anti-CGRP drugs 
approved in Poland (Fig. S5).
Discussion
In this study, only one neurologist knew the exact diag-
nostic criteria for migraine with and without aura. Less than 
a third of the responding neurologists listed some of the 
diagnostic criteria only for migraine without aura. 
It must be underlined that the neurologists participating 
in this study defined themselves as being those who regularly 
manage migraine patients and are experts in this field.
Our findings show that knowledge of the diagnostic cri-
teria for migraine among neurologists in Poland is very poor, 
which can lead to inappropriate treatment.
Our results are only partially in line with previous research, 
because in that previous research the problem was investigated 
only in relation to family doctors/primary care physicians. 
Gultekin et al. found that only one in 10 primary healthcare 
physicians was able to make a correct diagnosis of migraine 
[20]. In another study, 70% of patients with primary headache 
complaints did not receive a correct diagnosis from general 
practitioners [21]. It seems that educating doctors and patients 
on migraine symptoms is necessary in order to increase the 
recognition of migraine and to improve treatment outcomes, 
including the outcomes of preventive treatment.  
In 2016, migraine was ranked as the number one cause 
of years lived with disability in people aged 15–49, i.e. the 
sector of society who are the most occupationally active [22]. 
Patients with chronic migraine have considerably reduced 
health-related quality of life in physical, mental, and overall 
health aspects. The impact of migraine on life increases with 
the number of days on which migraine headaches occur [23].
Indeed, in the internet-based survey by Silberstein et al., 
headache-related disability, healthcare resource utilisation, 
and economic burden were found to increase gradually in 
patients presenting low-, moderate-, and high-frequency 
migraine, with the highest scores achieved in the chronic 
migraine subgroup [24].
Lack of effective treatment for migraine leads to frequent 
physician consultations, thereby generating substantial social 
and economic costs [25]. In 2017, the National Health Fund 
in Poland provided services for patients with migraine at 
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a total cost exceeding 7 million PLN [26]. The costs due to 
absenteeism (nearly 100,000 days annually) were estimated 
at nearly 31 million PLN. According to the Social Insurance 
Institution in Poland, patients with episodic migraine have 
decreased productivity for 3.3 days quarterly, and those with 
chronic migraine, for 15.7 days quarterly. In this study, more 
than 20% of patients with chronic migraine required sick leave 
that lasted for an average of seven days. 
Apart from the aforementioned absenteeism, presenteeism 
seems to be another, perhaps even more common and signifi-
cant, problem. It is much more difficult to evaluate and to count 
the economic consequences of incomplete functioning in the 
workplace because of a set of symptoms of migraine attack 
including not only headache but also nausea, vomiting, hyper-
responsiveness to light, sound, and smell, as well as avoiding 
any motor activities. Even though employees are physically at 
work, they are unable to concentrate, focus on work, and fully 
perform their duties. They do their jobs ineffectively, and are 
more likely to make mistakes. 
It is clear that the burden of migraine, particularly chronic 
migraine, is underestimated. 
In Poland, perhaps 1% of the general population might 
have chronic migraine, but fewer than half of those suffering 
from migraine receive medical help [26, 27].
Effective preventive treatment can reduce the economic 
costs of migraine. In practice, however, it is difficult to achieve 
effective migraine prevention. In this study, 40% of patients 
with chronic migraine received all available preventive treat-
ments, but without a satisfactory result. The main reasons for 
treatment discontinuation were a lack of effectiveness (61%) 
and adverse effects (41%). In the International Burden of Mi-
graine Study (IBMS-II), the reasons given for discontinuation 
were similar (lack of effectiveness ~40%; adverse effects ~40%). 
These findings indicate that there is a need for tolerable and 
effective preventive treatments for migraine [19].
The classic preventive oral treatments, including tricyclic 
antidepressants, β-blockers, calcium channel blockers, and 
antiepileptics, were not developed specifically for patients 
with migraine. In contrast, anti-CGRP-pathway monoclonal 
antibodies target CGRP or its receptor, a key neuropeptide 
which is implicated in the pathophysiology of migraine. Mo-
reover, these medications (anti-CGRP-pathway monoclonal 
antibodies) are much better tolerated and have almost no 
contraindications. 
With regard to the most serious adverse events due to 
some classic migraine prevention therapeutics, such as te-
ratogenicity and liver toxicity, there is currently no evidence 
that anti-CGRP-pathway monoclonal antibodies would cause 
such adverse events [28]. The efficacy and safety of four anti-
-CGRP-pathway monoclonal antibodies have been assessed in 
groups of both episodic and chronic migraine patients [29–37].
In a phase 3, randomised trial among patients with chronic 
migraine, the anti-CGRP monoclonal antibody fremane-
zumab, injected quarterly, reduced the number of headache 
days by 4.3 ± 0.3 per month and, when injected monthly, by 
4.6 ± 0.3 per month, compared to 2.5 ± 0.3 per month in the 
placebo group (p < 0.001 for both comparisons with place-
bo). Injection-site reactions to the drug were common. The 
most common adverse event was injection-site pain, which 
occurred with comparable frequency in all three groups (30%, 
26%, and 28%, respectively) [29]. In the FOCUS study among 
838 patients after the failure to up to four migraine preventive 
medication classes, fremanezumab monthly and quarterly re-
duced the number of days with migraine headache by 3.5 and 
3.1 per month compared to placebo respectively (p < 0.0001). 
Fremanezumab was well tolerated, and there were no safety 
concerns. The FOCUS study showed that patients with diffi-
cult-to-treat episodic or chronic migraine, who previously did 
not respond to up to four preventive medications, can achieve 
clinically meaningful improvement with fremanezumab [30]. 
Another anti-CGRP monoclonal antibody, galcanezumab, 
was assessed in prevention of episodic or chronic migraine 
in adult patients in three phase 3, randomised, double-blind, 
placebo-controlled studies: EVOLVE-1 [31], EVOLVE-2 [33], 
and REGAIN [34].
In the EVOLVE-2 trial, galcanezumab given to episodic 
migraine patients at a dose of 120 mg or 240 mg monthly 
reduced the number of days with migraine headache by 
2.02 ± 0.27 and 1.90 ± 0.27, respectively, compared to placebo 
(p < 0.001). Injection site pain was the most commonly repor-
ted treatment-emergent adverse event [33].
Erenumab, a monoclonal antibody targeting CGRP 
receptor, was assessed in patients with episodic migraine in 
the STRIVE trial. While significantly reducing the number of 
days with migraine (3.2 at a dose of 70 mg and 3.7 at a dose 
of 140 mg per month compared to 1.8 for placebo, p < 0.001), 
it showed a safety profile similar to that of the placebo [32]. 
It also proved to be efficacious and well tolerated in chronic 
migraine patients in a phase 2 clinical trial [35].
Eptinezumab, the only intravenous anti-CGRP monoc-
lonal antibody, was investigated in the PROMISE-1 study 
in patients with episodic migraine [36], and in the PROMI-
SE-2 study in patients with chronic migraine [37]. In both 
studies, it proved to be efficacious and well-tolerated. 
In conclusion, all four anti-CGRP-pathway drugs appear 
to be highly successful in both episodic and chronic migraine 
management, while presenting favourable safety profiles.
Our study showed that each neurologist could offer anti-
-CGRP-pathway treatment for the preventive treatment of
migraine to about four patients, i.e. about a third of patients
with chronic migraine and about 10% of all patients with
migraine. Of the four anti-CGRP-pathway monoclonal an-
tibodies developed to date, three are approved in Europe/
Poland (approved first by FDI, next by EMA), i.e. erenumab,
fremanezumab, and galcanezumab. Eptinezumab has not yet
been approved in Poland or Europe, but it has received FDA
approval [38]. About eight in 10 neurologists were aware
that erenumab was available in Poland, but only 6% and 2%
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knew of the approval of galcanezumab and fremanezumab, 
respectively. During the study period, only erenumab was 
available in Poland; fremanezumab also became available in 
November 2019.
The cost of anti-CGRP-pathway monoclonal antibodies 
is considerably higher than that of other drugs used for 
migraine prevention. However, since monoclonal antibodies 
targeting CGRP and its receptor have demonstrated strong 
and consistent efficacy, favourable tolerability, and no safety 
signals, they can reduce the direct and indirect costs of mi-
graine. Effectiveness, good tolerability, but also convenience 
of administration and, in our opinion, very high compliance 
and adherence, are evident advantages of anti-CGRP-pathway 
monoclonal antibodies. This kind of therapy may represent 
a valid option for episodic migraine and chronic migraine 
prevention in patients who are intolerant or who have inade-
quate response or contraindications to conventional preventive 
treatments [39]. Importantly, early treatment in patients with 
high-frequency episodic migraine may prevent progression 
from episodic to chronic migraine, thus reducing the burden 
on patients and society.
Conclusions and clinical implications
Migraine is underdiagnosed and undertreated in Poland. 
The diagnostic criteria for migraine used by neurologists in 
their practice are insufficient, mainly due to poor knowledge. 
Increasing migraine recognition will help to establish the 
number of patients who require treatment, including pre-
vention. Importantly, 40% of patients with chronic migraine 
receive all available preventive treatments used not only for the 
prevention of chronic migraine but also for treating episodic 
migraine, but without a satisfactory result. 
Anti-CGRP-pathway monoclonal antibodies are effective 
and have a favourable safety profile. Most neurologists in 
Poland see migraine patients in whom anti-CGRP-pathway 
treatment is both justified and indicated. 
Ethical permission: Ethical approval was not necessary for the 
preparation of this article.
Funding: This research was funded by Teva Pharmaceuticals 
Polska Sp. z o.o., Poland and was conducted in co-operation 
with PEX PharmaSequence, Poland.
We would like to thank all the physicians and interviewers 
involved in the research. Special thanks to Mrs. Katarzyna Proga, 
Mrs. Joanna Głażewska, and Mrs. Katarzyna Wróbel from PEX 
PharmaSequence.
Medical writing, professional editing, and language assistance 
was provided by Proper Medical Writing, Warsaw, Poland and 
sponsored by Teva Pharmaceuticals Polska Sp. z o.o., Poland. 
Conflicts of interest: A.L. is a Teva Pharmaceuticals Polska 
employee. The authors declare no conflicts of interest. All authors 
have read and approved the revised manuscript.
References 
1. Goadsby PJ. Bench to bedside advances in the 21st century for pri-
mary headache disorders: migraine treatments for migraine patients. 
Brain. 2016; 139(Pt 10): 2571–2577, doi: 10.1093/brain/aww236, 
indexed in Pubmed: 27671024.
2. GBD 2016 Neurology Collaborators, GBD 2016 Headache Collabora-
tors. Global, regional, and national burden of migraine and tension-ty-
pe headache, 1990-2016: a systematic analysis for the Global Burden
of Disease Study 2016. Lancet Neurol. 2018; 17(11): 954–976, doi:
10.1016/S1474-4422(18)30322-3, indexed in Pubmed: 30353868.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding
and treatment. N Engl J Med. 2002; 346(4): 257–270, doi: 10.1056/
NEJMra010917, indexed in Pubmed: 11807151.
4. Tepper SJ, Dahlöf CGH, Dowson A, et al. Prevalence and diagnosis
of migraine in patients consulting their physician with a compla-
int of headache: data from the Landmark Study. Headache. 2004;
44(9): 856–864, doi: 10.1111/j.1526-4610.2004.04167.x, indexed
in Pubmed: 15447694.
5. Domitrz I, Lipa A, Rozniecki J, et al. Polish omnibus online survey on
migraine conducted in a population of 2000 adults. Migrena news
2019;3(6):98-100, International Headache Congress Dublin 05-08; 2019.
6. Stępień A, Prusiński A, Suwała A. Selected epidemiological data on 
migraine prevalence in Poland. Ból. 2003; 3(4): 9–12.
7. Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine
and Severe Headache in the United States: Figures and Trends From 
Government Health Studies. Headache. 2018; 58(4): 496–505, doi:
10.1111/head.13281, indexed in Pubmed: 29527677.
8. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic
migraine: a systematic review. Cephalalgia. 2010; 30(5): 599–609,
doi: 10.1111/j.1468-2982.2009.01941.x, indexed in Pubmed:
19614702.
9. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comor-
bidity profiles of chronic migraine and episodic migraine sufferers. 
J Neurol Neurosurg Psychiatry. 2010; 81(4): 428–432, doi: 10.1136/
jnnp.2009.192492, indexed in Pubmed: 20164501.
10. The International Classification of Headache Disorders, 3rd edition. 
Cephalalgia. 2018; 38(1): 1–211.
11. Chalmer MA, Hansen TF, Lebedeva ER, et al. Proposed new diagnostic 
criteria for chronic migraine. Cephalalgia. 2020; 40(4): 399–406,
doi: 10.1177/0333102419877171, indexed in Pubmed: 31544467.
12. Chądzyński P, Kacprzak A, Domitrz W, et al. Migraine headache 
facilitators in a population of Polish women and their association
with migraine occurrence - preliminary results. Neurol Neurochir Pol.
2019; 53(5): 377–383, doi: 10.5603/PJNNS.a2019.0044, indexed
in Pubmed: 31592536.
13. Charles A. The pathophysiology of migraine: implications for clinical
management. The Lancet Neurology. 2018; 17(2): 174–182, doi:
10.1016/s1474-4422(17)30435-0.
14. Evers S, Afra J, Frese A, et al. European Federation of Neurological
Societies, Members of the task force:. EFNS guideline on the drug
treatment of migraine - report of an EFNS task force. Eur J Neurol.
2006; 13(6): 560–572, doi: 10.1111/j.1468-1331.2006.01411.x, 
indexed in Pubmed: 16796580.
15. Stępień A. Kryteria diagnostyczne i leczenie migreny w oparciu o obo-
wiązujące zalecenia międzynarodowe. Med Dypl. 2011; 9(186): 81–87.
16. Monteith T. Chronic Migraine: Epidemiology, Mechanisms, and Treatment. 
Chronic Headache. 2018: 37–62, doi: 10.1007/978-3-319-91491-6_4.
7www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Izabela Domitrz et al., Migraine in neurological ambulatory practice
17. Weatherall MW. The diagnosis and treatment of chronic mi-
graine. Ther Adv Chronic Dis. 2015; 6(3): 115–123, doi:
10.1177/2040622315579627, indexed in Pubmed: 25954496.
18. Ong JJ, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy 
for Migraine Prevention: From Pathophysiology to New Drugs. Drugs.
2018; 78(4): 411–437, doi: 10.1007/s40265-018-0865-y, indexed
in Pubmed: 29396834.
19. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and 
reasons for discontinuation of prophylactic medications for episodic
migraine and chronic migraine: results from the second international 
burden of migraine study (IBMS-II). Headache. 2013; 53(4): 644–
655, doi: 10.1111/head.12055, indexed in Pubmed: 23458496.
20. Gültekin M, Balci E, İsmaİLOĞULLARI S, et al. Awareness of Migraine 
Among Primary Care Physicians in Turkey: A Regional Study. Noro
Psikiyatr Ars. 2018; 55(4): 354–357, doi: 10.5152/npa.2016.19228, 
indexed in Pubmed: 30622393.
21. Kernick D, Stapley S, Hamilton W. GPs’ classification of headache: is 
primary headache underdiagnosed? Br J Gen Pract. 2008; 58(547):
102–104, doi: 10.3399/bjgp08X264072, indexed in Pubmed:
18307854.
22. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability 
in under 50s: will health politicians now take notice? J Headache
Pain. 2018; 19(1): 17, doi: 10.1186/s10194-018-0846-2, indexed in 
Pubmed: 29468450.
23. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and 
resource use among chronic and episodic migraineurs: results from
the International Burden of Migraine Study (IBMS). Cephalalgia.
2011; 31(3): 301–315, doi: 10.1177/0333102410381145, indexed
in Pubmed: 20813784.
24. Silberstein SD, Lee L, Gandhi K, et al. Health care Resource Utilization 
and Migraine Disability Along the Migraine Continuum Among Patients 
Treated for Migraine. Headache. 2018; 58(10): 1579–1592, doi:
10.1111/head.13421, indexed in Pubmed: 30375650.
25. Wang SJ, Fuh JL, Huang SY, et al. Taiwan MAP Study Group. Diagnosis 
and development of screening items for migraine in neurological pra-
ctice in Taiwan. J Formos Med Assoc. 2008; 107(6): 485–494, doi:
10.1016/S0929-6646(08)60157-6, indexed in Pubmed: 18583220.
26. Społeczne znaczenie migreny z perspektywy zdrowia publicznego i sy-
stemu ochrony zdrowia. Zakład Analiz Ekonomicznych i Systemowych 
Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny. 
2019: Warszawa.
27. Katarzyńska A, Domitrz I. Codzienny przewlekły ból głowy – historia, 
epidemiologia, klinika i przyszłość Neurologia i Neurochirurgia Polska. 
2009; 43(2): 155–161.
28. Sacco S, Bendtsen L, Ashina M, et al. European headache federation 
guideline on the use of monoclonal antibodies acting on the calcitonin 
gene related peptide or its receptor for migraine prevention. J Heada-
che Pain. 2019; 20(1): 6, doi: 10.1186/s10194-018-0955-y, indexed 
in Pubmed: 30651064.
29. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Pre-
ventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377(22): 
2113–2122, doi: 10.1056/NEJMoa1709038, indexed in Pubmed:
29171818.
30. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo
for migraine prevention in patients with documented failure to up to
four migraine preventive medication classes (FOCUS): a randomi-
sed, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;
394(10203): 1030–1040, doi: 10.1016/S0140-6736(19)31946-4, 
indexed in Pubmed: 31427046.
31. Stauffer VL, Dodick DW, Zhang Qi, et al. Evaluation of Galcanezumab 
for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized
Clinical Trial. JAMA Neurol. 2018; 75(9): 1080–1088, doi: 10.1001/
jamaneurol.2018.1212, indexed in Pubmed: 29813147.
32. Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab 
for Episodic Migraine. N Engl J Med. 2017; 377(22): 2123–2132, doi: 
10.1056/NEJMoa1705848, indexed in Pubmed: 29171821.
33. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of 
galcanezumab for the prevention of episodic migraine: Results of the 
EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia.
2018; 38(8): 1442–1454, doi: 10.1177/0333102418779543, inde-
xed in Pubmed: 29848108.
34. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic 
migraine: The randomized, double-blind, placebo-controlled REGA-
IN study. Neurology. 2018; 91(24): e2211–e2221, doi: 10.1212/
WNL.0000000000006640, indexed in Pubmed: 30446596.
35. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenu-
mab for preventive treatment of chronic migraine: a randomised,
double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;
16(6): 425–434, doi: 10.1016/S1474-4422(17)30083-2, indexed in 
Pubmed: 28460892.
36. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic mi-
graine: A randomized, double-blind, placebo-controlled stu-
dy (PROMISE-1). Cephalalgia. 2020; 40(3): 241–254, doi:
10.1177/0333102420905132, indexed in Pubmed: 32075406.
37. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptine-
zumab in patients with chronic migraine: PROMISE-2. Neurology. 2020; 
94(13): e1365–e1377, doi: 10.1212/WNL.0000000000009169, in-
dexed in Pubmed: 32209650.
38. h t t p s : / / w w w. a c c e s s d a t a . f d a . g o v / d r u g s a t f d a _ d o c s /
label/2020/761119s000lbl.pdf (22.02.2020).
39. Negro A, Martelletti P. Patient selection for migraine preventive treat-
ment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 
2019; 19(8): 769–776, doi: 10.1080/14737175.2019.1621749, in-
dexed in Pubmed: 31109209.
